Benzinga | Mar 15, 2021 08:14AM EDT

Scholar Rock To Present TOPAZ Interim Analysis Data For Apitegromab in Spinal Muscular Atrophy At 2021 Muscular Dystrophy Association Virtual Clinical & Scientific Conference Mar. 18

Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced its oral and poster presentations at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference, being held March 15-18.

Both presentations will include six-month interim analysis data from the TOPAZ Phase 2 clinical trial evaluating the potential of apitegromab, a highly selective inhibitor of latent myostatin, in improving motor function in patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA). Top-line clinical data from TOPAZ for the full 12-month treatment period are expected in the second quarter of 2021.

Oral presentation details:

* Title: Apitegromab, a Novel High-Affinity Anti-proMyostatin Monoclonal Antibody for Treating Spinal Muscular Atrophy: Results of a Phase 2 Interim Analysis

* Date and Time: Thursday, March 18, 2021, 2:00-2:15 pm EST

* Presenter: Amy Place, PhD, MBA, MS, RD, CLT on behalf of the apitegromab development team

Poster presentation details:

* Title: Apitegromab, a Novel High-Affinity Anti-Promyostatin Monoclonal Antibody for Treating Spinal Muscular Atrophy: Results of a Phase 2 Interim Analysis (Poster #51)

* Dates: Virtual poster presentations are available to view on the virtual conference platform from March 15-18, 2021